TP53 and hepatocellular carcinoma: according to Choi M’s report, E2F1 could overcome the effect of HBx on p53 promoter and it activated p53 promoter though the E2F1 binding site (19).gathering this and the relationship of p53 and E2F1/Rb in lobaplatin treatment, we could conclude that lobaplatin is involved in p53 apoptosis axis though its Proliferation inhibitance and progression of HCC.